Research advances in calcitonin gene-related peptides in treatment of migraine
Migraine is a common type of primary headache worldwide,and its high morbidity and disability rates have brought heavy burden to individuals and society,thereby requiring preventive and acute treatment.Previous thera-peutic strategies for migraine include traditional analgesics and triptans,which are mainly used to relieve pain and reduce accompanying symptoms,but long-term administration of such drugs may lead to medication overuse headache.In recent years,new drugs targeting calcitonin gene-related peptide(CGRP)and its receptors have shown a promising future in the preventive treatment of migraine and the treatment of migraine in the acute stage,such as monoclonal antibodies and small-molecular receptor antagonists,and in addition,they also can be used in patients who have no response to various pharma-cotherapies.This article reviews the recent advances in CGRP drugs in the treatment of migraine.
国家科技期刊平台
NSTL
万方数据
